Szwiec M, Tomiczek-Szwiec J, Marciniak W, Derkacz R, Huzarski T, Cybulski C
Cancers (Basel). 2025; 17(5).
PMID: 40075686
PMC: 11898521.
DOI: 10.3390/cancers17050839.
Papakonstantinou A, Villacampa G, Navarro V, Oliveira M, Valachis A, Pascual T
EClinicalMedicine. 2025; 81:103116.
PMID: 40034565
PMC: 11875833.
DOI: 10.1016/j.eclinm.2025.103116.
Moser S, Jonkers J
Cancer Discov. 2025; 15(3):461-480.
PMID: 40025950
PMC: 11893084.
DOI: 10.1158/2159-8290.CD-24-1326.
Boehm K, El Nahhas O, Marra A, Waters M, Jee J, Braunstein L
Nat Commun. 2025; 16(1):2106.
PMID: 40025017
PMC: 11873197.
DOI: 10.1038/s41467-025-57283-x.
Bonissoni M, Alves F, Almeida R, Smaniotto L, Berny M, Silva V
Acta Cir Bras. 2025; 40:e402025.
PMID: 40008719
PMC: 11849801.
DOI: 10.1590/acb402025.
Use of medications in women with triple-negative breast cancer between 2018 and 2019 in a Brazilian public hospital: a retrospective study.
Pires M, Sobreira-da-Silva M, Araujo P, Retto M
Epidemiol Serv Saude. 2025; 34:e20240180.
PMID: 40008715
PMC: 11845119.
DOI: 10.1590/S2237-96222025v34e20240180.en.
Screening tools for malignancy in patients with cryptogenic stroke: Systematic review.
Tieck M, Single C, Poli S, Kowarik M, Ziemann U, Mengel A
Eur Stroke J. 2025; :23969873241310760.
PMID: 40008556
PMC: 11866335.
DOI: 10.1177/23969873241310760.
Triple-Negative Breast Cancer Systemic Treatment: Disruptive Early-Stage Developments for Overcoming Stagnation in the Advanced Pipeline.
Alonso-Ron C, Vethencourt A, Gonzalez-Suarez E, Oruezabal R
Cancers (Basel). 2025; 17(4).
PMID: 40002228
PMC: 11853049.
DOI: 10.3390/cancers17040633.
Exploring the Potential of Adjuvant CDK4/6 Inhibitors in Hormone Receptor-Positive Early Breast Cancer: A Consistent Approach for All.
Li J
Cancers (Basel). 2025; 17(4).
PMID: 40002156
PMC: 11852482.
DOI: 10.3390/cancers17040561.
Treatments of Interest in Male Breast Cancer: An Umbrella Review.
Spinaci S, Arecco L, Anedda A, Martino L, Firpo E, Ghilli M
J Pers Med. 2025; 15(2).
PMID: 39997343
PMC: 11856642.
DOI: 10.3390/jpm15020066.
Concurrent Neoadjuvant Chemotherapy and Radiation in Locally Advanced Breast Cancer: Impact on Locoregional Recurrence Rates.
Grindrod N, Cecchini M, Brackstone M
Curr Oncol. 2025; 32(2).
PMID: 39996885
PMC: 11854545.
DOI: 10.3390/curroncol32020085.
Adjuvant radiotherapy in postmenopausal women with early-stage ER-positive breast cancer: A systematic review and meta-analysis.
Taha A, Kamel H, Khlidj Y, Salem D, Saed S, Abouelmagd K
Medicine (Baltimore). 2025; 104(8):e41632.
PMID: 39993075
PMC: 11857031.
DOI: 10.1097/MD.0000000000041632.
Real-World Observational Study of Incidence and Outcomes in an HR+/HER2- Early Breast Cancer Population with High-Risk of Recurrence in Finland.
Singh R, Tuominen S, Lassenius M, Auvinen M, Torstensson A, Wiklund T
Oncol Ther. 2025; 13(1):185-200.
PMID: 39951234
PMC: 11880475.
DOI: 10.1007/s40487-024-00324-0.
Clinico-pathological factors predicting pathological response in early triple-negative breast cancer.
Helal C, Djerroudi L, Ramtohul T, Laas E, Vincent-Salomon A, Jin M
NPJ Breast Cancer. 2025; 11(1):15.
PMID: 39948122
PMC: 11825670.
DOI: 10.1038/s41523-025-00729-8.
Tumor-Infiltrating Lymphocytes and Survival Outcomes in Early ERBB2-Positive Breast Cancer: 10-Year Analysis of the ShortHER Randomized Clinical Trial.
Dieci M, Bisagni G, Bartolini S, Schirone A, Cavanna L, Musolino A
JAMA Oncol. 2025; .
PMID: 39946142
PMC: 11826437.
DOI: 10.1001/jamaoncol.2024.6872.
Bacterial membrane-modified cerium oxide nanoboosters enhance systemic antitumor effects of radiotherapy in metastatic triple-negative breast cancer.
Chen S, Ng P, Lai C, Wang F, Wang Y, Chen M
J Nanobiotechnology. 2025; 23(1):105.
PMID: 39940015
PMC: 11823237.
DOI: 10.1186/s12951-025-03187-3.
Global evolution of breast cancer incidence in childbearing-age women aged 15-49 years: a 30-year analysis.
Xia C, Liu Y, Yong W, Qing X
J Cancer Res Clin Oncol. 2025; 151(2):75.
PMID: 39932566
PMC: 11814059.
DOI: 10.1007/s00432-025-06113-0.
Dose-dense anthracycline- and taxane-based chemotherapy remains the preferred treatment for selected patients with high-risk early breast cancer.
Lambertini M, Nordenskjold B
Lancet Reg Health Eur. 2025; 49:101212.
PMID: 39926309
PMC: 11804766.
DOI: 10.1016/j.lanepe.2025.101212.
Predicting axillary residual disease after neoadjuvant therapy in breast cancer using baseline MRI and ultrasound.
Malhaire C, Umay O, Cockenpot V, Selhane F, Ramtohul T, Reyal F
Eur Radiol. 2025; .
PMID: 39920303
DOI: 10.1007/s00330-025-11408-4.
TROPION-Breast04: a randomized phase III study of neoadjuvant datopotamab deruxtecan (Dato-DXd) plus durvalumab followed by adjuvant durvalumab versus standard of care in patients with treatment-naïve early-stage triple negative or HR-low/HER2-....
McArthur H, Tolaney S, Dent R, Schmid P, Asselah J, Liu Q
Ther Adv Med Oncol. 2025; 17:17588359251316176.
PMID: 39917260
PMC: 11800260.
DOI: 10.1177/17588359251316176.
